JAMA Dermatology publishes Phase 3 VALOR brepocitinib skin outcomes
JAMA Dermatology published skin-specific outcomes from the Phase 3 VALOR trial of brepocitinib in dermatomyositis, per TradingView News.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
ROIV ROIVW - JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis - Click For Relea
ROIV ROIVW - JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis